Alfasigma is one of the top 5 pharmaceutical companies in Italy, with a turnover in 2019 of more than 1 billion euros. It’s a private company with 75% owned by the family of the founder and 25% by two funds. The Alfasigma legacy is firmly anchored in a long lasting heritage of innovation and success, beginning in 1948 in Bologna (Italy) thanks to Marino Golinelli, the 100 years old philanthropist.
From the beginning Alfasigma has always pursued a twofold strategy:
– internally, a strong focus on Research & Development and Manufacturing around some proprietary
molecules, some of which represent more than 50% of the sales;
– externally, developing a robust strategy of mergers and acquisitions of other Italian and international companies (Sigma Tau, Pamlabs).
Currently Alfasigma has more than 3.000 employees worldwide, 17 direct branches and – through top
distributors – its presence spreads over more than 70 countries.